Literature DB >> 24270308

Modelling the incidence and mortality of psychotic disorders: data from the second Australian national survey of psychosis.

Sukanta Saha1, Harvey Whiteford, John McGrath.   

Abstract

OBJECTIVES: The aim of this study was to model estimates related to (a) the incidence of psychotic disorders and (b) the mortality associated with these disorders based on a large, population-based prevalence study.
METHODS: Data were drawn from the second national survey of adults with psychotic disorders conducted in seven Australian catchment areas during March to December 2010. To generate incidence rate estimates, we identified recent onset cases recruited as part of the prevalence study and then imputed population-based incidence rates using a set of conservative assumptions. Similarly, for mortality rates, we identified individuals who had died after being identified as 'screen-positive' for psychosis, but prior to full clinical assessment. Using a set of conservative assumptions, we then used these estimates to infer population-based mortality rates.
RESULTS: Based on our models, we estimated that the incidence rate for psychotic disorders was 28 cases per 100,000 population. The rate estimates were significantly higher in males than females, with an overall male:female ratio of 1.57:1. Incidence rate estimates peaked in the youngest age group (18-24 years). The adjusted mortality rate estimated during the whole period of observation was 12.5 per 1000 persons, with a standardised mortality ratio of 5.5.
CONCLUSIONS: Using treated prevalence data and observed deaths with appropriate algorithms, we were able to impute incidence and mortality rates for psychotic disorders consistent with the published literature. While the second national survey of psychotic disorders was not designed to identify mortality, our estimates provide a stark reminder of the increased mortality associated with these disorders.

Entities:  

Keywords:  Incidence; mortality; prevalence; psychosis; schizophrenia; standardised mortality ratio

Mesh:

Year:  2013        PMID: 24270308     DOI: 10.1177/0004867413513341

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  7 in total

1.  Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: Findings from the BEAR and BEARS-kid studies.

Authors:  Benno G Schimmelmann; Chantal Michel; Alexandra Martz-Irngartinger; Caroline Linder; Frauke Schultze-Lutter
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

Review 2.  Eating disorders and psychosis: Seven hypotheses.

Authors:  Mary V Seeman
Journal:  World J Psychiatry       Date:  2014-12-22

3.  National Prevalence of Mental Disorders among Incoming Canadian Male Offenders.

Authors:  Janelle N Beaudette; Lynn A Stewart
Journal:  Can J Psychiatry       Date:  2016-04-05       Impact factor: 4.356

Review 4.  Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.

Authors:  Petter Andreas Ringen; John A Engh; Astrid B Birkenaes; Ingrid Dieset; Ole A Andreassen
Journal:  Front Psychiatry       Date:  2014-09-26       Impact factor: 4.157

5.  Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker.

Authors:  Frank H Duffy; Eugene D'Angelo; Alexander Rotenberg; Joseph Gonzalez-Heydrich
Journal:  BMC Med       Date:  2015-11-02       Impact factor: 8.775

6.  Stepped Care, System Architecture and Mental Health Services in Australia.

Authors:  David Perkins
Journal:  Int J Integr Care       Date:  2016-09-14       Impact factor: 5.120

7.  The relationship between quality of life and physical fitness in people with severe mental illness.

Authors:  D Perez-Cruzado; A I Cuesta-Vargas; E Vera-Garcia; F Mayoral-Cleries
Journal:  Health Qual Life Outcomes       Date:  2018-05-02       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.